×
About 26,313 results

ALLMedicine™ Contraception Center

Research & Reviews  11,297 results

Trends in subdermal contraceptive implant use in Mexico 2009-2018: A population-based s...
https://doi.org/10.1002/ijgo.13744
International Journal of Gynaecology and Obstetrics: the ... Darney BG, Fuentes-Rivera E et. al.

May 17th, 2021 - The purpose of this study is to describe subdermal implant use in Mexico over time, by state, and by age. We conducted a repeated cross-sectional study using the 2009, 2014, and 2018 waves of the National Survey of Demographic Dynamics (ENADID). O...

An Updated Review on the Effects of Depot Medroxyprogesterone Acetate on the Mucosal Bi...
https://doi.org/10.1111/aji.13455
American Journal of Reproductive Immunology (New York, N.... Ayele H, Perner M et. al.

May 15th, 2021 - Access to safe, effective, and affordable contraception is important for women's health and essential to mitigate maternal and fetal mortality rates. The progestin-based contraceptive depot medroxyprogesterone acetate (DMPA) is a popular contracep...

Increasing uptake of long-acting reversible contraception with structured contraceptive...
https://doi.org/10.1111/1471-0528.16754
BJOG : an International Journal of Obstetrics and Gynaeco... Emtell Iwarsson K, Envall N et. al.

May 14th, 2021 - To evaluate the effect of structured contraceptive counselling on uptake of long-acting reversible contraceptives (LARCs), and pregnancy rates. Cluster randomised trial SETTING: Abortion, youth, and maternal health clinics in Stockholm, Sweden. Se...

Combined Oral Contraceptive Pill-Induced Hypertension and Hypertensive Disorders of Pre...
https://doi.org/10.1007/s11906-021-01147-4 10.1111/j.1744-4667.2012.00126.x 10.5812/ijem.4158 10.1016/0010-7824(95)00097-t 10.1161/01.hyp.11.3_pt_2.ii11 10.1016/j.lpm.2019.07.033 10.1097/aog.0000000000002114 10.15585/mmwr.mm6818e1 10.1016/j.jacc.2020.03.028 10.1016/j.ajog.2019.06.025 10.1016/j.bpobgyn.2011.01.006 10.1007/s11906-013-0329-4 10.1136/bmj.39335.385301.BE 10.1016/0891-5849(91)90039-6 10.1016/s0008-6363(01)00527-2 10.1001/jama.1977.03270500051024 10.1097/HJH.0b013e328346a5af 10.1161/01.hyp.33.1.90 10.1097/HJH.0000000000001310 10.1590/0034-7167-2017-0317 10.1161/HYPERTENSIONAHA.115.05179 10.1136/bmj.285.6339.403 10.1016/0002-9378(85)90418-1 10.1136/hrt.37.3.336 10.7759/cureus.2978 10.1002/14651858.CD003553.pub3 10.1177/003693308202700303 10.1161/01.cir.94.3.483 10.1016/0010-7824(95)00153-2 10.1016/s0010-7824(99)00079-7 10.1177/2047487318774847 10.1136/bmj.1.5907.533 10.1136/bmj.318.7176.96 10.1016/0002-9378(72)90811-3 10.1136/bmj.3.5875.317 10.1016/0002-9378(77)90390-8 10.1136/bmj.298.6667.165 10.1016/s0020-7292(97)00241-5 10.1016/s0010-7824(98)00018-3 10.1161/circresaha.118.313276 10.1001/jama.1991.03470020063033 10.1056/nejm199011153232003 10.1186/s12884-016-0852-9 10.1016/j.atherosclerosis.2018.05.051 10.1016/0010-7824(83)90023-9 10.1016/j.steroids.2019.01.005 10.1159/000299081 10.1016/0002-9378(94)90293-3 10.1210/jcem-49-3-346 10.1016/j.pbb.2013.05.007 10.1111/j.1365-2362.1975.tb00436.x 10.1210/edrv-16-5-608 10.1371/journal.pone.0144343 10.1210/er.2016-1065 10.1210/en.2013-1350 10.1210/jc.2003-030138 10.1203/PDR.0b013e31818d6c24 10.1016/j.tjog.2018.10.002 10.1016/0002-8703(84)90144-3 10.1210/jcem-63-4-1008 10.1152/ajpregu.2001.280.3.R807 10.1111/j.1365-2265.1983.tb03192.x 10.3109/10641969409067966 10.1161/hypertensionaha.116.07971 10.1177/1753944715624853 10.1161/HYPERTENSIONAHA.115.05267 10.1161/HYPERTENSIONAHA.118.10854 10.2337/diacare.28.8.1988 10.1097/01.AOG.0000437382.03963.88 10.1172/JCI4106 10.1385/ENDO:18:3:239 10.1258/om.2012.120007 10.1016/j.contraception.2008.07.002 10.1093/humrep/14.12.3080 10.1172/jci99026 10.1038/ng.3895 10.1172/JCI17189 10.1016/j.etap.2017.03.012 10.1016/j.preghy.2019.12.010 10.1016/j.placenta.2020.09.005 10.1517/14622416.3.1.57 10.1586/14779072.5.2.283 10.1111/1471-0528.15394 10.1016/s0010-7824(03)00073-8 10.1055/s-0042-107078 10.1016/j.ajog.2010.06.011 10.1016/j.preghy.2017.12.003 10.1016/j.placenta.2018.07.004 10.1097/HJH.0000000000000844 10.1038/nrendo.2011.122 10.1016/j.vph.2011.06.003 10.3892/mmr.2017.8165 10.1007/s00210-016-1272-0 10.1016/0960-0760(91)90270-f 10.1038/ng0593-59 10.1038/s41598-017-05411-z 10.1177/1470320317753924 10.1016/0002-9378(68)90345-1 10.1016/0002-9343(72)90054-x 10.1097/00004872-199204000-00007 10.1161/01.res.38.1.35 10.1161/01.HYP.0000190040.66563.04 10.1016/s1071-5576(02)00259-9 10.1038/ajh.2010.70 10.1038/nm.1856 10.1161/01.CIR.0000058200.90059.B1 10.2174/1389201019666180925121254 10.1152/ajpregu.1997.273.6.R1908 10.1002/jcla.22834 10.3390/ijms16034600 10.1016/s0010-7824(03)00006-4 10.1002/jcla.21492 10.1161/HYPERTENSIONAHA.114.04484 10.1016/j.preghy.2020.09.002 10.1016/j.ajog.2014.02.018 10.1002/ijgo.12455 10.1136/bmj.f5298 10.1111/jth.13349 10.1055/s-0037-1612973 10.1160/th16-10-0748 10.1016/s0049-3848(13)70009-4 10.1002/(sici)1096-8652(199903)60:3<175::aid-ajh1>3.0.co;2-x 10.1177/1076029616683802 10.1016/S1521-6926(03)00021-5 10.1093/bja/aev374 10.1055/s-0030-1270336 10.1371/journal.pone.0114488 10.1111/j.1365-2141.2005.05847.x 10.1093/ajh/hpw159 10.5551/jat.31591 10.6061/clinics/2016(04)11 10.11604/pamj.2019.33.200.16857 10.1097/00004872-200104000-00008 10.1093/oxfordjournals.aje.a114797 10.1161/HYPERTENSIONAHA.107.101873
Current Hypertension Reports; Gunaratne MDSK, Thorsteinsdottir B et. al.

May 13th, 2021 - Oral contraceptive pill-induced hypertension (OCPIH) and hypertensive disorders in pregnancy (HDP) share common risk factors and pathophysiological mechanisms, yet the bidirectional relationship between these two conditions is not well-established...

Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception.
https://www.ncbi.nlm.nih.gov/pubmed/33982994
American Family Physician; Steinberg J, Lynch SE

May 13th, 2021 - Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception.|2021|Steinberg J,Lynch SE,|

see more →

Guidelines  141 results

Society for Maternal-Fetal Medicine Consult Series #55: Counseling women at increased r...
https://doi.org/10.1016/j.ajog.2020.12.007
American Journal of Obstetrics and Gynecology; , Kaimal A et. al.

Dec 14th, 2020 - Women should be provided with evidence-based information when considering options for contraception and pregnancy management. When counseling about health conditions and available treatments, healthcare practitioners should employ strategies that ...

Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200366
Maturitas Ramírez I, De la Viuda E et. al.

Jun 5th, 2020 - COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antit...

Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recomm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147901
MMWR. Morbidity and Mortality Weekly Report; Tepper NK, Curtis KM et. al.

Apr 9th, 2020 - "U.S. Medical Eligibility Criteria for Contraceptive Use" (U.S. MEC) 2016 provides evidence-based guidance for the safe use of contraceptive methods among U.S. women with certain characteristics or medical conditions (1). The U.S. MEC is adapted f...

2020 American College of Rheumatology Guideline for the Management of Reproductive Heal...
https://doi.org/10.1002/art.41191
Arthritis & Rheumatology (Hoboken, N.J.) References; Sammaritano LR, Bermas BL et. al.

Feb 24th, 2020 - To develop an evidence-based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medic...

Over-the-Counter Access to Hormonal Contraception: ACOG Committee Opinion Summary, Number 788
https://journals.lww.com/greenjournal/Fulltext/2019/10000/Over_the_Counter_Access_to_Hormonal_Contraception_.41.aspx
Obstetrics & Gynecology;

Sep 24th, 2019 - ABSTRACT: Barriers to access are one reason for inconsistent or nonuse of contraception. The requirement for a prescription can be an obstacle for some contraceptive users. Several studies have demonstrated that women are capable of using self-scr...

see more →

Drugs  589 results see all →

Clinicaltrials.gov  12,753 results

Trends in subdermal contraceptive implant use in Mexico 2009-2018: A population-based s...
https://doi.org/10.1002/ijgo.13744
International Journal of Gynaecology and Obstetrics: the ... Darney BG, Fuentes-Rivera E et. al.

May 17th, 2021 - The purpose of this study is to describe subdermal implant use in Mexico over time, by state, and by age. We conducted a repeated cross-sectional study using the 2009, 2014, and 2018 waves of the National Survey of Demographic Dynamics (ENADID). O...

An Updated Review on the Effects of Depot Medroxyprogesterone Acetate on the Mucosal Bi...
https://doi.org/10.1111/aji.13455
American Journal of Reproductive Immunology (New York, N.... Ayele H, Perner M et. al.

May 15th, 2021 - Access to safe, effective, and affordable contraception is important for women's health and essential to mitigate maternal and fetal mortality rates. The progestin-based contraceptive depot medroxyprogesterone acetate (DMPA) is a popular contracep...

Increasing uptake of long-acting reversible contraception with structured contraceptive...
https://doi.org/10.1111/1471-0528.16754
BJOG : an International Journal of Obstetrics and Gynaeco... Emtell Iwarsson K, Envall N et. al.

May 14th, 2021 - To evaluate the effect of structured contraceptive counselling on uptake of long-acting reversible contraceptives (LARCs), and pregnancy rates. Cluster randomised trial SETTING: Abortion, youth, and maternal health clinics in Stockholm, Sweden. Se...

Combined Oral Contraceptive Pill-Induced Hypertension and Hypertensive Disorders of Pre...
https://doi.org/10.1007/s11906-021-01147-4 10.1111/j.1744-4667.2012.00126.x 10.5812/ijem.4158 10.1016/0010-7824(95)00097-t 10.1161/01.hyp.11.3_pt_2.ii11 10.1016/j.lpm.2019.07.033 10.1097/aog.0000000000002114 10.15585/mmwr.mm6818e1 10.1016/j.jacc.2020.03.028 10.1016/j.ajog.2019.06.025 10.1016/j.bpobgyn.2011.01.006 10.1007/s11906-013-0329-4 10.1136/bmj.39335.385301.BE 10.1016/0891-5849(91)90039-6 10.1016/s0008-6363(01)00527-2 10.1001/jama.1977.03270500051024 10.1097/HJH.0b013e328346a5af 10.1161/01.hyp.33.1.90 10.1097/HJH.0000000000001310 10.1590/0034-7167-2017-0317 10.1161/HYPERTENSIONAHA.115.05179 10.1136/bmj.285.6339.403 10.1016/0002-9378(85)90418-1 10.1136/hrt.37.3.336 10.7759/cureus.2978 10.1002/14651858.CD003553.pub3 10.1177/003693308202700303 10.1161/01.cir.94.3.483 10.1016/0010-7824(95)00153-2 10.1016/s0010-7824(99)00079-7 10.1177/2047487318774847 10.1136/bmj.1.5907.533 10.1136/bmj.318.7176.96 10.1016/0002-9378(72)90811-3 10.1136/bmj.3.5875.317 10.1016/0002-9378(77)90390-8 10.1136/bmj.298.6667.165 10.1016/s0020-7292(97)00241-5 10.1016/s0010-7824(98)00018-3 10.1161/circresaha.118.313276 10.1001/jama.1991.03470020063033 10.1056/nejm199011153232003 10.1186/s12884-016-0852-9 10.1016/j.atherosclerosis.2018.05.051 10.1016/0010-7824(83)90023-9 10.1016/j.steroids.2019.01.005 10.1159/000299081 10.1016/0002-9378(94)90293-3 10.1210/jcem-49-3-346 10.1016/j.pbb.2013.05.007 10.1111/j.1365-2362.1975.tb00436.x 10.1210/edrv-16-5-608 10.1371/journal.pone.0144343 10.1210/er.2016-1065 10.1210/en.2013-1350 10.1210/jc.2003-030138 10.1203/PDR.0b013e31818d6c24 10.1016/j.tjog.2018.10.002 10.1016/0002-8703(84)90144-3 10.1210/jcem-63-4-1008 10.1152/ajpregu.2001.280.3.R807 10.1111/j.1365-2265.1983.tb03192.x 10.3109/10641969409067966 10.1161/hypertensionaha.116.07971 10.1177/1753944715624853 10.1161/HYPERTENSIONAHA.115.05267 10.1161/HYPERTENSIONAHA.118.10854 10.2337/diacare.28.8.1988 10.1097/01.AOG.0000437382.03963.88 10.1172/JCI4106 10.1385/ENDO:18:3:239 10.1258/om.2012.120007 10.1016/j.contraception.2008.07.002 10.1093/humrep/14.12.3080 10.1172/jci99026 10.1038/ng.3895 10.1172/JCI17189 10.1016/j.etap.2017.03.012 10.1016/j.preghy.2019.12.010 10.1016/j.placenta.2020.09.005 10.1517/14622416.3.1.57 10.1586/14779072.5.2.283 10.1111/1471-0528.15394 10.1016/s0010-7824(03)00073-8 10.1055/s-0042-107078 10.1016/j.ajog.2010.06.011 10.1016/j.preghy.2017.12.003 10.1016/j.placenta.2018.07.004 10.1097/HJH.0000000000000844 10.1038/nrendo.2011.122 10.1016/j.vph.2011.06.003 10.3892/mmr.2017.8165 10.1007/s00210-016-1272-0 10.1016/0960-0760(91)90270-f 10.1038/ng0593-59 10.1038/s41598-017-05411-z 10.1177/1470320317753924 10.1016/0002-9378(68)90345-1 10.1016/0002-9343(72)90054-x 10.1097/00004872-199204000-00007 10.1161/01.res.38.1.35 10.1161/01.HYP.0000190040.66563.04 10.1016/s1071-5576(02)00259-9 10.1038/ajh.2010.70 10.1038/nm.1856 10.1161/01.CIR.0000058200.90059.B1 10.2174/1389201019666180925121254 10.1152/ajpregu.1997.273.6.R1908 10.1002/jcla.22834 10.3390/ijms16034600 10.1016/s0010-7824(03)00006-4 10.1002/jcla.21492 10.1161/HYPERTENSIONAHA.114.04484 10.1016/j.preghy.2020.09.002 10.1016/j.ajog.2014.02.018 10.1002/ijgo.12455 10.1136/bmj.f5298 10.1111/jth.13349 10.1055/s-0037-1612973 10.1160/th16-10-0748 10.1016/s0049-3848(13)70009-4 10.1002/(sici)1096-8652(199903)60:3<175::aid-ajh1>3.0.co;2-x 10.1177/1076029616683802 10.1016/S1521-6926(03)00021-5 10.1093/bja/aev374 10.1055/s-0030-1270336 10.1371/journal.pone.0114488 10.1111/j.1365-2141.2005.05847.x 10.1093/ajh/hpw159 10.5551/jat.31591 10.6061/clinics/2016(04)11 10.11604/pamj.2019.33.200.16857 10.1097/00004872-200104000-00008 10.1093/oxfordjournals.aje.a114797 10.1161/HYPERTENSIONAHA.107.101873
Current Hypertension Reports; Gunaratne MDSK, Thorsteinsdottir B et. al.

May 13th, 2021 - Oral contraceptive pill-induced hypertension (OCPIH) and hypertensive disorders in pregnancy (HDP) share common risk factors and pathophysiological mechanisms, yet the bidirectional relationship between these two conditions is not well-established...

Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception.
https://www.ncbi.nlm.nih.gov/pubmed/33982994
American Family Physician; Steinberg J, Lynch SE

May 13th, 2021 - Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception.|2021|Steinberg J,Lynch SE,|

see more →

News  1,531 results

Contraceptive and Pregnancy Planning Essential in Women With Heart Disease, Experts Advise
https://www.medscape.com/viewarticle/948879

Apr 8th, 2021 - NEW YORK (Reuters Health) - Women of childbearing age with, or at risk for, heart disease should be counseled on maternal and fetal risks of pregnancy, contraceptive safety and effectiveness and pregnancy planning options, the American College of ...

Emergency Contraception With the Progestin IUD
https://www.medscape.com/viewarticle/945624

Feb 21st, 2021 - This transcript has been edited for clarity. Hello. I'm Andrew Kaunitz, professor and associate chair in the ob/gyn department at the University of Florida College of Medicine in Jacksonville. Today I'd like to discuss the use of progestin intraut...

Levonorgestrel IUD Effective as Emergency Contraception
https://www.medscape.com/viewarticle/945354

Feb 4th, 2021 - A levonorgestrel 52-mg intrauterine device (IUD) is noninferior to a copper IUD for emergency contraception, according to randomized trial results published online in The New England Journal of Medicine. Although the trial didn't directly compare ...

Oral Contraceptives and Cancer: New Data
https://www.medscape.com/viewarticle/944559

Jan 26th, 2021 - This transcript has been edited for clarity. Hello. I'm Andrew Kaunitz, professor and associate chair in the ob/gyn department at the University of Florida, College of Medicine in Jacksonville. Today I'd like to discuss good news from Britain rega...

COVID-19 Impacts Women's Contraception Choices
https://www.medscape.com/viewarticle/942212

Dec 7th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The rate of unintended pregnancies in the United States has decreased to approximately 45%, based on data published in 2016, and "for the first ti...

see more →

Patient Education  2 results see all →